## Tardive Dyskinesia: Pathophysiology, Risk Factors, and Management ### Understanding Tardive Dyskinesia **Key Point:** Tardive dyskinesia (TD) is a late-onset involuntary movement disorder caused by chronic dopamine D2 receptor blockade. It is characterized by repetitive, involuntary movements of the orofacial region, limbs, and trunk that persist or emerge during antipsychotic treatment. ### Why Option 1 (Clozapine) Is Correct **High-Yield:** Clozapine is the ONLY antipsychotic with evidence-based data showing reversal of existing tardive dyskinesia. This is a unique property not shared by any other antipsychotic, including other second-generation agents. - Clozapine has the lowest D2 affinity of all antipsychotics - It has rapid dissociation kinetics from D2 receptors - Approximately 30–50% of patients with TD show improvement or resolution on clozapine - This makes clozapine the treatment of choice for antipsychotic-induced TD ### Why Option 2 (Switching to Aripiprazole) Is INCORRECT ← **CORRECT ANSWER** **Warning:** Simply switching from risperidone to another second-generation antipsychotic (such as aripiprazole, quetiapine, or olanzapine) does NOT reliably improve tardive dyskinesia. In fact: 1. **Persistence of TD**: Once TD develops, it often persists even after dose reduction or switching to a different antipsychotic 2. **Aripiprazole is not curative**: While aripiprazole has a lower TD risk than first-generation agents, it does NOT reverse existing TD 3. **Only clozapine has reversal evidence**: The evidence for TD improvement is specific to clozapine, not to second-generation antipsychotics in general 4. **Risk of worsening**: Abrupt discontinuation of the offending antipsychotic may paradoxically worsen TD (withdrawal dyskinesia) **Clinical Pearl:** The management algorithm for TD is: - **Step 1:** Reduce dose of current antipsychotic if possible (if symptoms permit) - **Step 2:** Switch to an antipsychotic with lowest TD risk (e.g., quetiapine, aripiprazole) - **Step 3:** If TD persists or worsens, switch to **clozapine** (the only agent with reversal evidence) - **Step 4:** Consider adjunctive benzodiazepines or beta-blockers for symptomatic relief ### Why Option 3 (Risk Factors) Is Correct **Mnemonic: AGED-FM** — Risk factors for tardive dyskinesia: - **A**ge (>50 years) - **G**ender (female > male, 1.5–2× risk) - **E**arly-onset psychosis - **D**uration of antipsychotic use (>5 years) - **F**irst-generation antipsychotics (higher risk than second-generation) - **M**ood disorder comorbidity (bipolar disorder, depression) The statement is correct: age, female gender, and mood disorder comorbidity all increase TD risk. ### Why Option 4 (AIMS Monitoring) Is Correct **High-Yield:** The AIMS (Abnormal Involuntary Movement Scale) is the gold-standard screening tool for TD. Guidelines recommend: | Timing | Frequency | Rationale | |--------|-----------|----------| | **Baseline** | Before starting antipsychotic | Establish absence of pre-existing TD | | **Ongoing** | Every 6–12 months | Early detection of incident TD | | **If TD suspected** | Immediate assessment | Confirm diagnosis and severity | Regular AIMS monitoring allows early detection and intervention before TD becomes severe and potentially irreversible. ### Summary Table: Antipsychotics and TD Risk | Antipsychotic | TD Risk | TD Reversal Evidence | Mechanism | |---|---|---|---| | Haloperidol (1st-gen) | Very high | No | Non-selective D2 blockade | | Chlorpromazine (1st-gen) | High | No | Non-selective D2 blockade | | Risperidone (2nd-gen) | Moderate | No | Moderate D2 affinity | | Olanzapine (2nd-gen) | Low | No | Lower D2 affinity | | Quetiapine (2nd-gen) | Very low | No | Very low D2 affinity | | Aripiprazole (2nd-gen) | Low | No | Partial D2 agonist | | **Clozapine** (2nd-gen) | **Very low** | **YES (30–50%)** | **Lowest D2 affinity, rapid off-rate** | [cite:KD Tripathi 8e Ch 12]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.